RaQualia Pharma, Inc.

RaQualia Pharma, Inc.

RaQualia Pharma, Inc.

Overview
Date Founded

2008

Headquarters

Meieki Southside Square, 8/F,1-21-19 Meikei Minami,Nakamura-Ku,Nagoya, Aichi 450-0003

Type of Company

Public

Employees (Worldwide)

68

Industries

Pharmaceuticals

Company Description

RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist. The company was founded on February 19, 2008 and is headquartered in Nagoya, Japan.

Executives & Employees

Representative Director

Chief Financial Officer, Director & Managing Executive Director

Executive Officer & Head-Drug Discovery Research

Director, Head-Personnel & Legal Affairs

Vice President

Board of Directors

Representative Director at RaQualia Pharma, Inc.

Executive Officer & Head-Drug Discovery Research at RaQualia Pharma, Inc.

Independent Outside Director at PCI Holdings, Inc.

Auditor at TMRC Co. Ltd.

Independent Outside Director at RaQualia Pharma, Inc.

Director at Sumitomo Electric U.S.A. Holdings, Inc.

Chief Financial Officer, Director & Managing Executive Director at RaQualia Pharma, Inc.

Paths to RaQualia Pharma, Inc.
Potential Connections via
Relationship Science
You
RaQualia Pharma, Inc.
Recent Transactions
Details Hidden

RaQualia Pharma, Inc. purchases TMRC Co. Ltd.

Details Hidden

RaQualia Pharma, Inc. issued JPY Ordinary Shares

Transaction Advisors
Underwriter

Advised onRaQualia Pharma, Inc. issued JPY Ordinary Shares

Underwriter

Advised onRaQualia Pharma, Inc. issued JPY Ordinary Shares

Underwriter

Advised onRaQualia Pharma, Inc. issued JPY Ordinary Shares

Clients

CJ Corp. engages in managing investments. The company through its subsidiaries operates in the following businesses: Food and Food services, Retail and Logistics, Entertainment and Media, Infrastructure, and Life Science. The company was founded on August 1, 1953 and is headquartered in Seoul, South Korea.

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Kolmar Korea Co., Ltd. engages in the original design manufacturing and original equipment manufacturing of cosmetics and pharmaceuticals. It operates through the following business areas: Cosmetics, Pharmaceuticals and Health Functional Foods. The Cosmetics business offers skin care, make up, perfume, quasi drugs, hair care and body care. The Pharmaceuticals business provides specialized medicines, general medicines, bio-equivalence medicine, contract process and quasi drugs. The Health Functional Foods business offers functional health foods, new material development, special foods and other individual sectors. The company was founded on May 15, 1990 and is headquartered in Sejong, South Korea.

Key Stats and Financials As of 2019
Market Capitalization
$210M
Total Enterprise Value
$232M
Earnings Per Share
$0
EBITDAMargin
7.29%
Enterprise Value / Sales
14.94x
Enterprise Value EBITDAOperating
205.06x
TEVNet Income
4,763.12x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
34.16%
Revenue
$15.5M
Net Profit
$48.7K
EBITDA
$1.13M
Total Debt
$21.9K
Total Equity
$42.1M
Investments
Details Hidden

Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

Investors
Details Hidden

Representative Director at RaQualia Pharma, Inc.

Details Hidden

UTEC is an active manager which invests in Japanese startup companies. The firm invests in companies in the technology sectors. UTECinvests as a minority shareholder requiring a seat in the board of directors. The firm particularly targets seed and early stage companies.

Suppliers
Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by RaQualia Pharma, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of RaQualia Pharma, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and RaQualia Pharma, Inc..